Next Generation of CO2 Incubators for Demanding Cell Culture Applications
Cell culture scientists working with sensitive cultures such as stem and primary cells, can turn to a new CO2 incubator that combines the latest technologies for optimal cell growth and contamination control designed to create uniform growth conditions with consistency and reliability.
The Thermo Scientific Heracell VIOS incubator series is ideal for academic research and pharmaceutical applications, allowing scientists to maximize their productivity with excellent reproducibility, reliability and efficiency.
“Reproducibility and contamination prevention are critical when it comes to sensitive cultures to ensure the integrity of your research,” said Doug Wernerspach, Global Business Director, Thermo Fisher Scientific. “Our new Heracell VIOS series leverage our long history of CO2 technology leadership with innovations, including our new THRIVE active airflow and proven decontamination that are critical for today’s demanding cell culture applications.”
Incorporating the breakthrough THRIVE active airflow technology, the Heracell VIOS delivers a homogeneous culturing environment with fast recovery for unwanted variation. Designed to protect valuable cultures from contamination, the Heracell VIOS is equipped with
• ISO class 5 HEPA filters to protect against airborne microbes and particulates
• Steri-Run, a fully automatic on-demand overnight 180 °C sterilisation cycle assures uniform 6-log high-temperature sterilisation on all surfaces
• Condensation-free chamber with covered, protected humidity reservoir
• 100% pure copper interiors to provide lasting sustainability and easy maintenance.
For operation simplicity, the intelligent iCAN touchscreen interface provides complete data visibility to monitor all incubator interaction, featuring on-screen menu prompts, error and usage monitoring, downloadable data logging with a standard USB, performance trend graphing and multiple language selection, including English, Spanish, German, French, Italian, Japanese and Mandarin.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...